Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K4 | P45985 | 18/20 | 0.66 |
| ▸ | MAP2K7 | O14733 | 4/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | MAPK6 | Q16659 | 2/20 | 0.51 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.51 |
| ▸ | MAPKAPK3 | Q16644 | 1/20 | 0.51 |
| ▸ | JAK2 | O60674 | 1/20 | 0.50 |
| ▸ | ITK | Q08881 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17829662 | 0.87 | MAP2K4 (0.82) | MAP2K4MAP2K7MAPK1MAPK6MAPKAPK2 | |
| SCHEMBL27191587 | 0.80 | MAP2K4 (1.00) | MAP2K4MAP2K7MAPK1MAPK6MAPKAPK2 | |
| SCHEMBL17829699 | 0.79 | MAP2K4 (0.69) | MAP2K4MAP2K7MAPK1MAPK6MAPKAPK2 | |
| SCHEMBL17829602 | 0.79 | MAP2K4 (0.69) | MAP2K4MAP2K7MAPK1MAPK6MAPKAPK2 | |
| SCHEMBL4056313 | 0.77 | MAP2K4 (0.48) | MAP2K4MAP2K7MAPK1JAK2 | |
| SCHEMBL9271850 | 0.77 | MAP2K4 (0.64) | MAP2K4MAP2K7MAPK1MAPK6MAPKAPK2 | |
| SCHEMBL17829604 | 0.77 | MAP2K4 (0.66) | MAP2K4MAP2K7MAPK1MAPK6MAPKAPK2 | |
| SCHEMBL27191596 | 0.75 | MAP2K4 (1.00) | MAP2K4MAP2K7MAPK1MAPK6MAPKAPK3 | |
| SCHEMBL22819388 | 0.74 | MAP2K4 (1.00) | MAP2K4MAP2K7 | |
| SCHEMBL27191600 | 0.74 | MAP2K4 (1.00) | MAP2K4MAP2K7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160168140-A1 | HETEROCYCLIC COMPOUNDS AS ANTIBIOTIC POTENTIATORS | SYNERECA PHARMACEUTICALS (US) | 2016-06-16 | — | — | US | disclosed |
| US-20160168140-A1 | HETEROCYCLIC COMPOUNDS AS ANTIBIOTIC POTENTIATORS | SYNERECA PHARMACEUTICALS (US) | 2016-06-16 | — | — | US | disclosed |
| WO-2016094730-A1 | HETEROCYCLIC COMPOUNDS AS ANTIBIOTIC POTENTIATORS | SYNERECA PHARMACEUTICALS, INC. (US) | 2016-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160168140-A1 | HETEROCYCLIC COMPOUNDS AS ANTIBIOTIC POTENTIATORS | FOS, FOSB, YAP1 | MAP2K4 793/4885MAP2K7 1257/4885MAPK1 192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.